Citable filing context
IQV's research view summarizes recent SEC filing context, starting with debt_offering from Sep 23, 2026.
| Filed | Item | Context |
|---|---|---|
| Sep 23, 2026 | debt_offering | IQVIA Inc. issued $2 billion in 6.375% senior notes due 2034. |
| Sep 9, 2026 | debt_offering | IQVIA priced $2 billion in senior notes due 2034 at a 6.375% interest rate. |
| Jul 28, 2026 | earnings | IQVIA reported second-quarter 2026 revenue of $4.368 billion, up 8.7% year-over-year, and raised its full-year 2026 guidance. |
| Jul 28, 2026 | Guidance: adjusted_diluted_eps | 12.80 to 13.00 |
| Jul 28, 2026 | Guidance: adjusted_ebitda | 4000.00 to 4050.00 |
| Jul 28, 2026 | Guidance: revenue | 17275.00 to 17475.00 |
| Jul 28, 2026 | mda_quarterly | IQVIA reported strong financial performance for the first half of 2026, with total revenues reaching $8.52 billion, an 8.6% increase over the prior-year period. Growth was driven by both reportable segments: Commercial Solutions, which grew 10.1% to $3.55 billion, and Research & Development Solutions, which rose 7.5% to $4.97 billion. The R&D segment remains a primary revenue driver, supported by a robust contracted backlog of $34.2 billion, of which $9.2 billion is expected to convert to revenue within the next twelve months. Effective January 1, 2026, the company reorganized its reporting structure, consolidating Contract Sales & Medical Solutions into the renamed Commercial Solutions segment and shifting certain Real-World offerings into the R&D segment. Operating expenses rose due to higher compensation costs and increased restructuring efforts aimed at streamlining global operations. Liquidity remains stable with $1.91 billion in cash and cash equivalents. During the first half of 2026, IQVIA issued €950 million in 4.625% senior notes due 2033 to refinance debt, including a 364-day term loan. The company continues to prioritize shareholder returns, repurchasing $950 million of common stock and increasing its total repurchase authorization to $15.73 billion. Management remains in compliance with all material debt covenants. |
| May 5, 2026 | mda_quarterly | IQVIA reported total revenues of $4.15 billion for the first quarter of 2026, an 8.4% increase over the same period in 2025. This growth was driven by a 6.0% increase in constant currency revenue, with Commercial Solutions contributing $1.75 billion and Research & Development Solutions contributing $2.40 billion. The company recently reorganized its reporting structure, consolidating Contract Sales & Medical Solutions into the renamed Commercial Solutions segment and shifting certain Real-World offerings into the Research & Development Solutions segment. Operating performance remains robust, with income from operations rising to $514 million from $496 million in the prior year. The Research & Development Solutions segment maintains a strong contracted backlog of $34.2 billion, with approximately $8.9 billion expected to convert to revenue within the next twelve months. Liquidity remains stable, with $1.95 billion in cash and cash equivalents. During the quarter, IQVIA utilized a new $650 million Term Loan due 2027 to retire €550 million of 1.750% senior notes. The company continues to execute its capital allocation strategy, repurchasing $552 million of common stock during the quarter. Management expects ongoing restructuring efforts to continue through 2027 to streamline operations and integrate recent acquisitions. |
Source: SEC EDGAR filing text and events; period Sep 23, 2026; filed Sep 23, 2026.
IQV company research is free during early access. All you need is an account, with no card required. The five showcase tickers (TSLA, NVDA, AAPL, AMZN, PLTR) and the macro dashboard stay open without one.
Continue research
Follow same-sector companies and source explainers connected to the research view.
A factual guide to SEC Form 8-K current reports and the material company events they can disclose between quarterly filings.
A factual guide to quarterly SEC Form 10-Q reports, how they differ from annual 10-K filings, and what readers can inspect first.
A factual guide to Form S-1 registration statements and the disclosures companies provide before a public offering.
A factual guide to the core 10-K sections investors use for company context: business description, risk factors, MD&A, financial statements, and segment disclosures.